Keywords:
Abdomen, Oncology, Gastrointestinal tract, CT, MR, Staging, Cancer, Cirrhosis
Authors:
S. Fiore, E. Caramia, M. Gatti, L. J. Pavan, S. Molinaro, A. Depaoli, R. Faletti, P. Fonio; Turin/IT
DOI:
10.1594/ecr2018/C-1169
References
1.
Bruix J,
Sherman M.
Management of hepatocellular carcinoma: an update.
Hepatology 2011; 53: 1020–22.
2.
European Association for the Study of the Liver,
European Organisation for Research and treatment of Cancer.
EASL–EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma.
J.
Hepatol.
2012; 56: 908–43.
3.
Verslype C,
Rosmorduc O,
Rougier P; ESMO Guidelines Working Group.
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis,
treatment and follow-up.
Ann Oncol.
2012 Oct;23 Suppl 7:vii41-8.
4.
Ye F,
Liu J,
Ouyang H.
Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid (Gd-EOB-DTPA)-Enhanced Magnetic Resonance Imaging and Multidetector-Row Computed Tomography for the Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Medicine (Baltimore).
2015 Aug;94 (32):e1157.
5.
Renzulli M,
Golfieri R; Bologna Liver Oncology Group (BLOG).
Proposal of a new diagnostic algorithm for hepatocellular carcinoma based on the Japanese guidelines but adapted to the Western world for patients under surveillance for chronic liver disease.
J Gastroenterol Hepatol.
2016 Jan; 31(1):69-80.
6.
Hwang J,
Kim SH,
Lee MW,
et al.
Small (2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT.
Br J Radiol.
2012;85:e314– e322.